Protalix Biotherapeutics

PLX · NYSE American

$2.64+$0.08 (+3.13%)TodayMarket closed · Oct 20, 8:00 PM ET

Prev close $2.56

PLX analyst rating

BuyConsensus of 1 analyst over the last 12 months. 100% rate it a buy.

Strong buy0
Buy1
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $11.22 (+325.0% upside)

Low: $10.10
Now: $2.64
High: $12.60

Upgrades and downgrades

The latest rating actions, newest first

PLX analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Sep 9, 2026	Maintains	Buy	$12.00	43%
HC Wainwright & Co.	Mar 19, 2026	Maintains	Buy	$12.00	43%
HC Wainwright & Co.	Nov 21, 2025	Maintains	Buy	$15.00 → $12.00	43%

The case for and against

Updated May 15, 2024

Bull case

Protalix BioTherapeutics is in a strong position to dominate the market with its taliglucerase alfa drug, BioManguinhos alfataliglicerase in Brazil and Amended Pfizer Agreement. Driven by its robust pipeline of products and potential market penetration, the company is poised to achieve peak sales of $626M in the U.S. and ~$140M in Europe. With a projected diluted net loss per share of $0.16 in 2023, we maintain a Buy rating and raise our 12-month price target to $10 from $7, reflecting the attractive market metrics and potential growth ahead.

Bear case

Protalix BioTherapeutics is facing significant risks, with recent developments such as Chiesi reducing their milestone payments by $25 million and a continued lack of market traction for their product Elfabrio. Their partnerships with Chiesi and Pfizer also pose potential risks, and there may be operational disruptions due to the ongoing conflict in Israel. In addition, there is a possibility of long-term dilution for the company. The recent decrease in milestone payments and lack of market success is reflected in the projected net loss of $0.08 per share in 2024 and potential operational disruptions due to the conflict.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.